Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

Kangstem Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	5,856	4,681	7,542	9,969	7,681
Short-Term Investments	31,504	31,008	39,018	24,801	7,000
Trading Asset Securities	-	988.82	10,026	3,164	33,543
Cash & Short-Term Investments	37,360	36,678	56,585	37,933	48,224
Cash Growth	1.86%	-35.18%	49.17%	-21.34%	28.00%
Accounts Receivable	721.6	1,567	1,225	660.58	332.51
Other Receivables	411.99	651.07	326.35	213.8	52.06
Receivables	1,134	2,218	1,551	874.38	384.57
Inventory	578.26	467.15	763.77	354.86	266.39
Prepaid Expenses	330.83	330.06	326.96	26.09	38.16
Other Current Assets	7,963	6,213	6,128	5,562	6,495
Total Current Assets	47,366	45,907	65,355	44,751	55,408
Property, Plant & Equipment	29,572	31,265	34,126	34,794	34,978
Long-Term Investments	2,950	1,833	2,198	670	20,633
Other Intangible Assets	440.12	1,041	991.53	1,121	1,789
Long-Term Accounts Receivable	-0	-0	-0	-0	0
Other Long-Term Assets	925.66	546.68	477.68	1,169	835.79
Total Assets	81,253	80,592	103,148	82,505	113,644
Accounts Payable	324.27	406.56	850.37	385.4	616.81
Accrued Expenses	483.99	436.08	421.19	304.28	284.76
Short-Term Debt	2,616	2,566	2,264	2,198	12,345
Current Portion of Long-Term Debt	5,530	3,700	3,500	355.56	83.33
Current Portion of Leases	808.9	752.43	844.37	829.4	472.54
Current Unearned Revenue	330	334.05	235.77	300.01	522.08
Other Current Liabilities	8,501	6,072	9,074	7,833	6,274
Total Current Liabilities	18,594	14,267	17,191	12,206	20,599
Long-Term Debt	3,380	5,230	5,630	12,427	14,804
Long-Term Leases	1,274	1,120	1,805	2,348	3,228
Other Long-Term Liabilities	6,375	6,301	6,323	6,144	5,579
Total Liabilities	31,130	27,890	31,862	33,866	44,924
Common Stock	27,969	18,969	18,969	12,418	10,425
Additional Paid-In Capital	174,895	163,374	163,374	131,311	134,808
Retained Earnings	-159,354	-137,201	-117,054	-95,670	-77,232
Comprehensive Income & Other	4,469	4,194	2,751	3,290	1,100
Total Common Equity	47,978	49,336	68,039	51,350	69,101
Minority Interest	-3,494	-2,110	-2,070	-2,981	-2,001
Shareholders' Equity	50,123	52,702	71,286	48,639	68,719
Total Liabilities & Equity	81,253	80,592	103,148	82,505	113,644
Total Debt	13,609	13,369	14,044	18,159	30,933
Net Cash (Debt)	23,751	23,309	42,542	19,775	17,291
Net Cash Growth	1.90%	-45.21%	115.13%	14.37%	-14.67%
Net Cash Per Share	584.98	614.40	1527.64	886.87	829.71
Filing Date Shares Outstanding	55.94	37.94	37.94	24.84	20.85
Total Common Shares Outstanding	55.94	37.94	37.94	24.84	20.85
Working Capital	28,772	31,640	48,165	32,544	34,809
Book Value Per Share	857.70	1300.44	1793.43	2067.50	3314.26
Tangible Book Value	47,538	48,295	67,048	50,229	67,311
Tangible Book Value Per Share	849.83	1273.00	1767.30	2022.35	3228.44
Land	8,249	7,984	7,984	7,798	1,243
Buildings	10,920	10,596	10,596	10,211	2,762
Machinery	595.05	590.8	533.4	539.11	522.21
Construction In Progress	310.22	23.52	50.96	-	25,964

Source: S&P Global Market Intelligence. Standard template. Financial Sources.